HK1207983A1 - Compositions comprising an anti-pdgf aptamer and a vegf antagonist pdgf vegf - Google Patents

Compositions comprising an anti-pdgf aptamer and a vegf antagonist pdgf vegf

Info

Publication number
HK1207983A1
HK1207983A1 HK15108671.2A HK15108671A HK1207983A1 HK 1207983 A1 HK1207983 A1 HK 1207983A1 HK 15108671 A HK15108671 A HK 15108671A HK 1207983 A1 HK1207983 A1 HK 1207983A1
Authority
HK
Hong Kong
Prior art keywords
pdgf
vegf
compositions
aptamer
antagonist
Prior art date
Application number
HK15108671.2A
Other languages
English (en)
Chinese (zh)
Inventor
Byeong Seon Chang
Richard Everett
Original Assignee
Ophthotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophthotech Corp filed Critical Ophthotech Corp
Publication of HK1207983A1 publication Critical patent/HK1207983A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
HK15108671.2A 2012-06-01 2015-09-06 Compositions comprising an anti-pdgf aptamer and a vegf antagonist pdgf vegf HK1207983A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654672P 2012-06-01 2012-06-01
US201361778208P 2013-03-12 2013-03-12
PCT/US2013/043536 WO2013181495A2 (en) 2012-06-01 2013-05-31 Compositions comprising an anti-pdgf aptamer and a vegf antagonist

Publications (1)

Publication Number Publication Date
HK1207983A1 true HK1207983A1 (en) 2016-02-19

Family

ID=49674074

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108671.2A HK1207983A1 (en) 2012-06-01 2015-09-06 Compositions comprising an anti-pdgf aptamer and a vegf antagonist pdgf vegf

Country Status (18)

Country Link
US (1) US20150182623A1 (xx)
EP (1) EP2854844A4 (xx)
JP (1) JP2015519373A (xx)
KR (1) KR20150033620A (xx)
CN (1) CN104619335A (xx)
AR (1) AR091237A1 (xx)
AU (1) AU2013267310A1 (xx)
CA (1) CA2874412A1 (xx)
CL (1) CL2014003233A1 (xx)
CO (1) CO7240393A2 (xx)
EA (1) EA201492289A1 (xx)
HK (1) HK1207983A1 (xx)
IL (1) IL235797A0 (xx)
MX (1) MX2014014445A (xx)
PH (1) PH12014502577A1 (xx)
SG (1) SG11201407981RA (xx)
TW (1) TW201400122A (xx)
WO (1) WO2013181495A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2915255A1 (en) 2013-07-12 2015-01-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3194029A1 (en) * 2014-08-11 2017-07-26 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
CN105435221B (zh) * 2014-09-22 2021-09-28 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
CN105806830B (zh) * 2015-12-10 2019-01-29 北京联众泰克科技有限公司 一种稳定的hrp酶促化学发光底物液、其制备方法及应用
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
WO2017129685A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
JP7081818B2 (ja) * 2016-02-04 2022-06-07 エーディーエス・セラピューティクス・エルエルシー 疾患治療のための抗体－薬剤相乗作用技術
WO2017147293A1 (en) * 2016-02-23 2017-08-31 Eleven Biotherapeutics, Inc. Il-6 antagonist formulations and uses thereof
CN116327963A (zh) * 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
KR20200089282A (ko) * 2017-11-20 2020-07-24 저스트-에보텍 바이오로직스, 아이엔씨. 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
SG11202010684YA (en) 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
US20210353713A1 (en) * 2018-10-26 2021-11-18 Amgen Inc. Formulations comprising a tris buffer and a protein
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
KR20210077645A (ko) * 2019-12-17 2021-06-25 주식회사 프로젠 신규 주사제 제형
JP2023516377A (ja) * 2020-03-04 2023-04-19 上海復宏漢霖生物技術股▲フン▼有限公司 ベバシズマブを含む薬物製剤
KR20220013343A (ko) * 2020-07-24 2022-02-04 (주) 팬젠 안과용 액상 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2281885A1 (en) * 2003-08-27 2011-02-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
SI2364691T1 (sl) * 2006-06-16 2013-08-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
CA2760687A1 (en) * 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
US9046513B2 (en) * 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof

Also Published As

Publication number Publication date
KR20150033620A (ko) 2015-04-01
SG11201407981RA (en) 2015-01-29
CL2014003233A1 (es) 2015-06-19
WO2013181495A3 (en) 2014-02-13
EP2854844A2 (en) 2015-04-08
AU2013267310A1 (en) 2014-12-11
CN104619335A (zh) 2015-05-13
WO2013181495A2 (en) 2013-12-05
PH12014502577A1 (en) 2015-01-21
EA201492289A1 (ru) 2015-05-29
CA2874412A1 (en) 2013-12-05
CO7240393A2 (es) 2015-04-17
MX2014014445A (es) 2015-08-14
IL235797A0 (en) 2015-01-29
JP2015519373A (ja) 2015-07-09
US20150182623A1 (en) 2015-07-02
TW201400122A (zh) 2014-01-01
AR091237A1 (es) 2015-01-21
EP2854844A4 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
HK1207983A1 (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist pdgf vegf
HK1211599A1 (en) Il-6 antagonists and uses thereof il-6
IL244599A0 (en) Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
HK1185329A1 (en) A method and an elevator arrangement
EP2823306A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2918315A4 (en) ARROW GAME
EP2816453A4 (en) TOUCH TYPE INPUT TERMINAL
GB201317376D0 (en) Viral load testing
GB2506381B (en) Automated detection of harmful content
SG2013091848A (en) An elevator
PL2671662T3 (pl) Urządzenie do zgrzewania rezystancyjnego
EP2894722A4 (en) THICK HEADED
HK1197563A1 (en) Load testing machine
HUE051449T2 (hu) Kilövõ alkatrész bõrkapcsolóval való használatra és bõrkapcsoló
SG2013067103A (en) Testing a fuse
GB2508174B (en) Detecting application behavior
GB201221341D0 (en) Pallets
EP2921248A4 (en) WELD STRUCTURE AND MACHINERY
FR2998538B1 (fr) Trampoline amphibie
PT2601214T (pt) Composições de antagonistas de vegf e utilizações destes
EP2803993A4 (en) AUTOMATIC SAMPLER
IL239426A0 (en) Methods and compositions of biomarkers
GB201501821D0 (en) An animal barrier
EP2827096A4 (en) FINGER
TWM433649U (en) Large-current terminal